Search

Author/Creator Ott, Patrick A

1. A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in patients (pts) at high risk for recurrence. (4th November 2015)

Authors:
Weber, Jeffrey; Grob, Jean-Jaques; Margolin, Kim A; Ascierto, Paolo A; Sznol, Mario; Ott, Patrick A; Lejeune, Chantal; de Pril, Veerle; Ruisi, Mary M; Hodi, F Stephen
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 3(2015)Supplement 2
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Issue 11 (November 2016)

Authors:
Hodi, F Stephen; Chesney, Jason; Pavlick, Anna C; Robert, Caroline; Grossmann, Kenneth F; McDermott, David F; Linette, Gerald P; Meyer, Nicolas; Giguere, Jeffrey K; Agarwala, Sanjiv S; Shaheen, Montaser; Ernstoff, Marc S; Minor, David R; Salama, April K; Taylor, Matthew H; Ott, Patrick A; Horak, ...
Journal:
Lancet oncology
Issue:
Volume 17:Issue 11(2016:Nov.)
Page Start:
1558
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study. Issue 7 (23rd July 2021)

Authors:
Sanborn, Rachel E; Hamid, Omid; de Vries, Elisabeth GE; Ott, Patrick A; Garcia-Corbacho, Javier; Boni, Valentina; Bendell, Johanna; Autio, Karen A; Cho, Daniel C; Plummer, Ruth; Stroh, Mark; Lu, Lawrence; Thistlethwaite, Fiona
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 9:Issue 7(2021)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors. Issue 10 (27th October 2022)

Authors:
Hamid, Omid; Chiappori, Alberto A; Thompson, John A; Doi, Toshihiko; Hu-Lieskovan, Siwen; Eskens, Ferry A L M; Ros, Willeke; Diab, Adi; Spano, Jean-Philippe; Rizvi, Naiyer A; Wasser, Jeffrey S; Angevin, Eric; Ott, Patrick A; Forgie, Alison; Yang, Wenjing; Guo, Cen; Chou, Jeffrey; El-Khoueiry, Ant...
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 10:Issue 10(2022)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Issue 7 (July 2016)

Authors:
Antonia, Scott J; López-Martin, José A; Bendell, Johanna; Ott, Patrick A; Taylor, Matthew; Eder, Joseph Paul; Jäger, Dirk; Pietanza, M Catherine; Le, Dung T; de Braud, Filippo; Morse, Michael A; Ascierto, Paolo A; Horn, Leora; Amin, Asim; Pillai, Rathi N; Evans, Jeffry; Chau, Ian; Bono, Petri; At...
Journal:
Lancet oncology
Issue:
Volume 17:Issue 7(2016:Jul.)
Page Start:
883
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Issue 11 (November 2016)

Authors:
Sharma, Padmanee; Callahan, Margaret K; Bono, Petri; Kim, Joseph; Spiliopoulou, Pavlina; Calvo, Emiliano; Pillai, Rathi N; Ott, Patrick A; de Braud, Filippo; Morse, Michael; Le, Dung T; Jaeger, Dirk; Chan, Emily; Harbison, Chris; Lin, Chen-Sheng; Tschaika, Marina; Azrilevich, Alex; Rosenberg, Jon...
Journal:
Lancet oncology
Issue:
Volume 17:Issue 11(2016:Nov.)
Page Start:
1590
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study. (May 2022)

Authors:
Marabelle, Aurelien; Cassier, Philippe A; Fakih, Marwan; Kao, Steven; Nielsen, Dorte; Italiano, Antoine; Guren, Tormod Kyrre; van Dongen, Marloes G J; Spencer, Kristen; Bariani, Giovanni Mendonca; Ascierto, Paolo A; Santoro, Armando; Shah, Manisha; Asselah, Jamil; Iqbal, Syma; Takahashi, Shunji; ...
Journal:
Lancet gastroenterology and hepatology
Issue:
Volume 7:Number 5(2022)
Page Start:
446
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032. (4th November 2015)

Authors:
Taylor, Matthew; Antonia, Scott; Bendell, Johanna; Calvo, Emiliano; Jäger, Dirk; de Braud, Filippo; Ott, Patrick A; Pietanza, M Catherine; Horn, Leora; Le, Dung T; Morse, Michael A; López-Martin, José A; Ascierto, Paolo A; Christensen, Olaf; Simon, Jason S; Lin, Chen-Sheng; Eder, Joseph Paul
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 3(2015)Supplement 2
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗